ABSTRACT
THE AIM OF THE STUDY: Is to investigate the opportunity of emtricitabine extraction from biomaterial and to develop method of emtricitabine chemicotoxicological analysis while acute poisoning. This research represents the methods of emtricitabine isolation from urine, plasma and liver samples (rats of Wistar line weighing 180 g) using liquid-liquid extraction. The identification and quantitation methods of emtricitabine in extractions by thin-layer chromatography, ultraviolet spectrophotometry and high-performance liquid chromatography methods were described. The emtricitabine was found extracted from urine with a therapeutic dose of 6.65±2.21 µg/ml and a toxic dose 35.81±1.05 µg/ml, from plasma with a therapeutic dose of 2.91±0.19 µg/ml and a toxic dose of 16.88±0.90 µg/ml.
Subject(s)
Biocompatible Materials , Liquid-Liquid Extraction , Rats , Animals , Emtricitabine , Rats, Wistar , Spectrophotometry, Ultraviolet/methods , Chromatography, High Pressure Liquid/methodsABSTRACT
THE AIM OF THE STUDY: Was to investigate the distribution of (±)-N-methyl-3-phenyl-3-(para-trifluoromethyl) phenoxypropylamine hydrochloride (fluoxetine) in the body of warm-blooded animals. For the experiments, Wistar rats were used. Fluoxetine was isolated from animal organs and bio-liquids by liquid-liquid extraction. Thin layer chromatography, UV spectrophotometry, and high performance liquid chromatography were used for identification and quantification. Techniques for isolating fluoxetine from urine, blood, intestinal contents, kidneys, and liver samples using liquid-liquid extraction are presented. Methods for identification and quantitative determination of fluoxetine in extracts by thin layer chromatography, UV spectrophotometry, and high performance liquid chromatography are described. The greatest amount of fluoxetine was found in the kidneys - 12.94±2.18 mg/100 g, the small intestine with contents - 9.50±1.90 mg/100 g and liver - 9.28±1.37 mg/100 g.
Subject(s)
Fluoxetine , Animals , Chromatography, High Pressure Liquid , Chromatography, Thin Layer , Fluoxetine/pharmacokinetics , Rats , Rats, Wistar , Spectrophotometry , Spectrophotometry, Ultraviolet , Tissue DistributionABSTRACT
Comparative data are presented for the choleretic activity of xanthones isolated from Gentianopsis barbata (Froel.) Ma. (Gentianaceae family): a sum of xanthone glycosides (I) and aglycons (II); xanthone aglycons, including decussatin [1-(OH)-3,7,8-(OCH3)3] (III) and gentiacaulein [1,7-(OH)-3,8-(OCH3)2] (IV); and xanthone glycoside gentiabavaroside [1-O-primverosyl-7-(OH)-3,8-(OCH3)2] (V). It was established that (II) is superior to (I) with respect to cholagogic effect and is inferior to (III) and (IV) with respect to cholatostimulant action.
Subject(s)
Cholagogues and Choleretics/pharmacology , Gentianaceae , Xanthenes/pharmacology , Animals , Bile/chemistry , Bile/metabolism , Cholagogues and Choleretics/chemistry , Female , Male , Plant Extracts/chemistry , Plant Extracts/pharmacology , Rats , Structure-Activity Relationship , Xanthenes/chemistryABSTRACT
The granulated dry extract from Gentianopsis barbata (Froel) Ma in a dose of 0.1 g/kg produced a pronounced therapeutic effect in rats with experimental toxic (tetrachloromethane) and drug-induced (tetracycline) hepatitis. The gentian extract improved the bile production and secretion functions of liver, normalized the protein, lipid, and pigment metabolism, and increased the antioxidant system activity in the test animals.